View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
February 25, 2021

Quest Diagnostics unveils new Covid-19 testing service

Quest Diagnostics has unveiled a new Covid-19 semi-quantitative serology testing service that helps in offering insight into a person’s immune response to prior SARS-CoV-2 infection or Covid-19 vaccination.

Quest Diagnostics has unveiled a new Covid-19 semi-quantitative serology testing service that offers insight into a person’s immune response to prior SARS-CoV-2 infection or Covid-19 vaccination.

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

Approximately 40% of SARS-CoV-2-infected people do not experience symptoms. Serology tests can detect people who have developed antibodies that could provide protection from future infection and detect those still at risk, the US F ood and Drug Administration (F DA) said.

The test service delivers a positive or negative result and a numerical result that could offer the basis for analysing relative changes in antibody blood levels.

F urthermore, it can help in evaluating blood antibody levels produced to structural proteins of the SARS-CoV-2 spike protein.

As vaccines that are currently available in the US have mRNA that encodes the spike protein, the test could show an immune response, resulting from an infection or vaccination.

The company noted that the test cannot distinguish between immune response mounted in response to infection or vaccination.

Quest Diagnostics senior vice-president and chief medical officer Jay Wohlgemuth said: “We believe that SARS CoV-2 semi-quantitative serology testing will be an important clinical tool to assess if an individual has mounted an immune response from recent or prior infection or vaccination.

“These insights may aid clinical management of certain patients at high risk of severe Covid-19 disease or who may be at risk for vaccination such as people with a history of severe vaccine allergy or women who are pregnant.

“Importantly, we also believe semi-quantitative testing will improve public health surveillance as researchers across the US seek to better understand the contributions of vaccination and prior infections on herd immunity.”

Last July, the F DA granted emergency use authorisation (EUA) for specimen pooling with Quest Diagnostics ‘ Covid-19 diagnostic test.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network